Published on 15 Aug 2022 on Zacks via Yahoo Finance
Glaukos Corporation GKOS is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. The strength in the iStent product line and solid execution across its global glaucoma and Corneal Health franchises augur well. The sustained recovery trends across segments and solid business prospects in spite of the pandemic-induced uncertainties raise optimism. Recent strategic alliances instill confidence in the stock.
The company is also engaged in boosting its portfolio through the development of new products. The company currently has 13 publicly-disclosed programs and another 10 yet-to-be-disclosed development programs underway. A number of these pipeline programs are in active pivotal clinical trials, including iStent infinite and iDose TR.
However, stiff competition in the medical device industry and vendor uncertainty are other headwinds. Meanwhile, a stringent regulatory approval process for the iDose platform and products is a woe.